Anti-inflammatory therapeutic approaches to reduce acute atherosclerotic complications

Current Pharmaceutical Biotechnology

Volumn 13, Issue 1, 2012, Pages 37-45

  Kanzler, Isabella ^a   Liehn, Elisa A ^a   Koenen, Rory R ^a,b   Weber, Christian ^a,b,c  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Antagonist; Atherosclerosis; Chemokine; Ischemia reperfusion; Myocardial infarction

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCL2; CHEMOKINE RECEPTOR CCL5; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCL10; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CP 481; MARAVIROC; MC 21; MC 68; MIGRATION INHIBITION FACTOR; MLN 1202; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; OPIATE; PA 508; PLERIXAFOR; UNCLASSIFIED DRUG; VICRIVIROC;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL FUNCTION; CELL MIGRATION; DRUG TARGETING; HUMAN; LEUKOCYTE; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; CHEMOKINES; HUMANS; RECEPTORS, CHEMOKINE;

EID: 84855829768     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112798868557     Document Type: Article

References (113)

1. Murray, C. J.; Lopez, A. D. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet, 1997, 349(9061), 1269-1276.
2. Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med., 2005, 352(16), 1685-1695.
3. Weber, C.; Zernecke, A.; Libby, P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat. Rev. Immunol., 2008, 8(10), 802-815.
4. Ley, K.; Laudanna, C.; Cybulsky, M. I.; Nourshargh, S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol., 2007, 7(9), 678-689.
5. Liehn, E. A.; Zernecke, A.; Postea, O.; Weber, C. Chemokines: inflammatory mediators of atherosclerosis. Arch. Physiol. Biochem., 2006, 112(4-5), 229-238.
6. von Hundelshausen, P.; Weber, K. S.; Huo, Y.; Proudfoot, A. E.; Nelson, P. J.; Ley, K.; Weber, C. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation, 2001, 103(13), 1772-1777.
7. Schober, A.; Manka, D.; von Hundelshausen, P.; Huo, Y.; Hanrath, P.; Sarembock, I. J.; Ley, K.; Weber, C. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation, 2002, 106(12), 1523-1529.
8. Landsman, L.; Bar-On, L.; Zernecke, A.; Kim, K. W.; Krauthgamer, R.; Shagdarsuren, E.; Lira, S. A.; Weissman, I. L.; Weber, C.; Jung, S. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood, 2009, 113(4), 963-972.
9. Huo, Y.; Weber, C.; Forlow, S. B.; Sperandio, M.; Thatte, J.; Mack, M.; Jung, S.; Littman, D. R.; Ley, K. The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J. Clin. Invest., 2001, 108(9), 1307-1314.
10. Weber, K. S.; von Hundelshausen, P.; Clark-Lewis, I.; Weber, P. C.; Weber, C. Differential immobilization and hierarchical involvement of chemokines in monocyte arrest and transmigration on inflamed endothelium in shear flow. Eur. J. Immunol., 1999, 29(2), 700-712.
11. Schober, A.; Zernecke, A.; Liehn, E. A.; von Hundelshausen, P.; Knarren, S.; Kuziel, W. A.; Weber, C. Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets. Circ. Res., 2004, 95(11), 1125-1133.
12. Balabanian, K.; Lagane, B.; Infantino, S.; Chow, K. Y.; Harriague, J.; Moepps, B.; Arenzana-Seisdedos, F.; Thelen, M.; Bachelerie, F. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J. Biol. Chem., 2005, 280(42), 35760-35766.
13. Schober, A.; Knarren, S.; Lietz, M.; Lin, E. A.; Weber, C. Crucial role of stromal cell-derived factor-1alpha in neointima formation after vascular injury in apolipoprotein E-deficient mice. Circulation, 2003, 108(20), 2491-2497.
14. Zernecke, A.; Schober, A.; Bot, I.; von Hundelshausen, P.; Liehn, E. A.; Mopps, B.; Mericskay, M.; Gierschik, P.; Biessen, E. A.; Weber, C. SDF-1alpha/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ. Res., 2005, 96(7), 784-791.
15. Salcedo, R.; Oppenheim, J. J. Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation, 2003, 10(3-4), 359-370.
16. Charo, I. F.; Ransohoff, R. M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med., 2006, 354(6), 610-621.
17. Proudfoot, A. E.; Handel, T. M.; Johnson, Z.; Lau, E. K.; LiWang, P.; Clark-Lewis, I.; Borlat, F.; Wells, T. N.; Kosco-Vilbois, M. H. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc. Natl. Acad. Sci. U. S. A., 2003, 100(4), 1885-1890.
18. Proudfoot, A. E. The biological relevance of chemokineproteoglycan interactions. Biochem. Soc. Trans., 2006, 34(Pt 3), 422-426.
19. Salanga, C. L.; O'Hayre, M.; Handel, T. Modulation of chemokine receptor activity through dimerization and crosstalk. Cell. Mol. Life Sci., 2009, 66(8), 1370-1386.
20. Suzuki, S.; Chuang, L. F.; Yau, P.; Doi, R. H.; Chuang, R. Y. Interactions of opioid and chemokine receptors: oligomerization of mu, kappa, and delta with CCR5 on immune cells. Exp. Cell Res., 2002, 280(2), 192-200.
21. Springael, J. Y.; Urizar, E.; Parmentier, M. Dimerization of chemokine receptors and its functional consequences. Cytokine Growth Factor Rev., 2005, 16(6), 611-623.
22. Proudfoot, A. E.; Power, C. A.; Rommel, C.; Wells, T. N. Strategies for chemokine antagonists as therapeutics. Semin. Immunol., 2003, 15(1), 57-65.
23. Rothenbacher, D.; Muller-Scholze, S.; Herder, C.; Koenig, W.; Kolb, H. Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. Arterioscler. Thromb. Vasc. Biol., 2006, 26(1), 194-199.
24. Cavusoglu, E.; Eng, C.; Chopra, V.; Clark, L. T.; Pinsky, D. J.; Marmur, J. D. Low plasma RANTES levels are an independent predictor of cardiac mortality in patients referred for coronary angiography. Arterioscler. Thromb. Vasc. Biol., 2007, 27(4), 929-935.
25. Kraaijeveld, A. O.; de Jager, S. C.; de Jager, W. J.; Prakken, B. J.; McColl, S. R.; Haspels, I.; Putter, H.; van Berkel, T. J.; Nagelkerken, L.; Jukema, J. W.; Biessen, E. A. CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms. Circulation, 2007, 116(17), 1931-1941.
26. Aukrust, P.; Halvorsen, B.; Yndestad, A.; Ueland, T.; Oie, E.; Otterdal, K.; Gullestad, L.; Damas, J. K. Chemokines and cardiovascular risk. Arterioscler. Thromb. Vasc. Biol., 2008, 28(11), 1909-1919.
27. Weber, C.; Schober, A.; Zernecke, A. Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler. Thromb. Vasc. Biol., 2004, 24(11), 1997-2008.
28. Krohn, R.; Raffetseder, U.; Bot, I.; Zernecke, A.; Shagdarsuren, E.; Liehn, E. A.; van Santbrink, P. J.; Nelson, P. J.; Biessen, E. A.; Mertens, P. R.; Weber, C. Y-box binding protein-1 controls CC chemokine ligand-5 (CCL5) expression in smooth muscle cells and contributes to neointima formation in atherosclerosis-prone mice. Circulation, 2007, 116(16), 1812-1820.
29. Braunersreuther, V.; Zernecke, A.; Arnaud, C.; Liehn, E. A.; Steffens, S.; Shagdarsuren, E.; Bidzhekov, K.; Burger, F.; Pelli, G.; Luckow, B.; Mach, F.; Weber, C. Ccr5 but not Ccr1 deficiency re duces development of diet-induced atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol., 2007, 27(2), 373-379.
30. Zernecke, A.; Liehn, E. A.; Gao, J. L.; Kuziel, W. A.; Murphy, P. M.; Weber, C. Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. Blood, 2006, 107(11), 4240-4243.
31. Liehn, E. A.; Merx, M. W.; Postea, O.; Becher, S.; Djalali-Talab, Y.; Shagdarsuren, E.; Kelm, M.; Zernecke, A.; Weber, C. Ccr1 deficiency reduces inflammatory remodelling and preserves left ventricular function after myocardial infarction. J. Cell. Mol. Med., 2008, 12(2), 496-506.
32. Dobaczewski, M.; Xia, Y.; Bujak, M.; Gonzalez-Quesada, C.; Frangogiannis, N. G. CCR5 signaling suppresses inflammation and reduces adverse remodeling of the infarcted heart, mediating recruitment of regulatory T cells. Am. J. Pathol., 2010, 176(5), 2177-2187.
33. Veillard, N. R.; Kwak, B.; Pelli, G.; Mulhaupt, F.; James, R. W.; Proudfoot, A. E.; Mach, F. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ. Res., 2004, 94(2), 253-261.
34. Braunersreuther, V.; Steffens, S.; Arnaud, C.; Pelli, G.; Burger, F.; Proudfoot, A.; Mach, F. A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler. Thromb. Vasc. Biol., 2008, 28(6), 1090-1096.
35. Braunersreuther, V.; Pellieux, C.; Pelli, G.; Burger, F.; Steffens, S.; Montessuit, C.; Weber, C.; Proudfoot, A.; Mach, F.; Arnaud, C. Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. J. Mol. Cell. Cardiol., 2010, 48(4), 789-798.
36. Makino, Y.; Cook, D. N.; Smithies, O.; Hwang, O. Y.; Neilson, E. G.; Turka, L. A.; Sato, H.; Wells, A. D.; Danoff, T. M. Impaired T cell function in RANTES-deficient mice. Clin. Immunol., 2002, 102(3), 302-309.
37. Tyner, J. W.; Uchida, O.; Kajiwara, N.; Kim, E. Y.; Patel, A. C.; O'Sullivan, M. P.; Walter, M. J.; Schwendener, R. A.; Cook, D. N.; Danoff, T. M.; Holtzman, M. J. CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Nat. Med., 2005, 11(11), 1180-1187.
38. Koenen, R. R.; Weber, C. Therapeutic targeting of chemokine interactions in atherosclerosis. Nat. Rev. Drug Discov., 2010, 9(2), 141-153.
39. Koenen, R. R.; von Hundelshausen, P.; Nesmelova, I. V.; Zernecke, A.; Liehn, E. A.; Sarabi, A.; Kramp, B. K.; Piccinini, A. M.; Paludan, S. R.; Kowalska, M. A.; Kungl, A. J.; Hackeng, T. M.; Mayo, K. H.; Weber, C. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat. Med., 2009, 15(1), 97-103.
40. Liang, M.; Mallari, C.; Rosser, M.; Ng, H. P.; May, K.; Monahan, S.; Bauman, J. G.; Islam, I.; Ghannam, A.; Buckman, B.; Shaw, K.; Wei, G. P.; Xu, W.; Zhao, Z.; Ho, E.; Shen, J.; Oanh, H.; Subramanyam, B.; Vergona, R.; Taub, D.; Dunning, L.; Harvey, S.; Snider, R. M.; Hesselgesser, J.; Morrissey, M. M.; Perez, H. D. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J. Biol. Chem., 2000, 275(25), 19000-19008.
41. Vilardaga, J. P.; Nikolaev, V. O.; Lorenz, K.; Ferrandon, S.; Zhuang, Z.; Lohse, M. J. Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling. Nat. Chem. Biol., 2008, 4(2), 126-131.
42. Botker, H. E.; Kharbanda, R.; Schmidt, M. R.; Bottcher, M.; Kaltoft, A. K.; Terkelsen, C. J.; Munk, K.; Andersen, N. H.; Hansen, T. M.; Trautner, S.; Lassen, J. F.; Christiansen, E. H.; Krusell, L. R.; Kristensen, S. D.; Thuesen, L.; Nielsen, S. S.; Rehling, M.; Sorensen, H. T.; Redington, A. N.; Nielsen, T. T. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet, 2010, 375(9716), 727-734.
43. Rentoukas, I.; Giannopoulos, G.; Kaoukis, A.; Kossyvakis, C.; Raisakis, K.; Driva, M.; Panagopoulou, V.; Tsarouchas, K.; Vavetsi, S.; Pyrgakis, V.; Deftereos, S. Cardioprotective role of remote ischemic periconditioning in primary percutaneous coronary intervention: enhancement by opioid action. JACC Cardiovasc. Interv., 2010, 3(1), 49-55.
44. Contento, R. L.; Molon, B.; Boularan, C.; Pozzan, T.; Manes, S.; Marullo, S.; Viola, A. CXCR4-CCR5: a couple modulating T cell functions. Proc. Natl. Acad. Sci. U. S. A., 2008, 105(29), 10101-10106.
45. Hernanz-Falcon, P.; Rodriguez-Frade, J. M.; Serrano, A.; Juan, D.; del Sol, A.; Soriano, S. F.; Roncal, F.; Gomez, L.; Valencia, A.; Martinez, A. C.; Mellado, M. Identification of amino acid residues crucial for chemokine receptor dimerization. Nat. Immunol., 2004, 5(2), 216-223.
46. Horuk, R.; Clayberger, C.; Krensky, A. M.; Wang, Z.; Grone, H. J.; Weber, C.; Weber, K. S.; Nelson, P. J.; May, K.; Rosser, M.; Dunning, L.; Liang, M.; Buckman, B.; Ghannam, A.; Ng, H. P.; Islam, I.; Bauman, J. G.; Wei, G. P.; Monahan, S.; Xu, W.; Snider, R. M.; Morrissey, M. M.; Hesselgesser, J.; Perez, H. D. A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. J. Biol. Chem., 2001, 276(6), 4199-4204.
47. Horuk, R.; Shurey, S.; Ng, H. P.; May, K.; Bauman, J. G.; Islam, I.; Ghannam, A.; Buckman, B.; Wei, G. P.; Xu, W.; Liang, M.; Rosser, M.; Dunning, L.; Hesselgesser, J.; Snider, R. M.; Morrissey, M. M.; Perez, H. D.; Green, C. CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model. Immunol. Lett., 2001, 76(3), 193-201.
48. Chen, X.; Oppenheim, J. J.; Howard, O. M. Chemokines and chemokine receptors as novel therapeutic targets in rheumatoid arthritis (RA): inhibitory effects of traditional Chinese medicinal components. Cell. Mol. Immunol., 2004, 1(5), 336-342.
49. Mack, M.; Cihak, J.; Simonis, C.; Luckow, B.; Proudfoot, A. E.; Plachy, J.; Bruhl, H.; Frink, M.; Anders, H. J.; Vielhauer, V.; Pfirstinger, J.; Stangassinger, M.; Schlondorff, D. Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J. Immunol., 2001, 166(7), 4697-4704.
50. Inoshima, I.; Kuwano, K.; Hamada, N.; Hagimoto, N.; Yoshimi, M.; Maeyama, T.; Takeshita, A.; Kitamoto, S.; Egashira, K.; Hara, N. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary fibrosis in mice. Am. J. Physiol. Lung Cell. Mol. Physiol., 2004, 286(5), L1038-1044.
51. Lloyd, C. M.; Minto, A. W.; Dorf, M. E.; Proudfoot, A.; Wells, T. N.; Salant, D. J.; Gutierrez-Ramos, J. C. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J. Exp. Med., 1997, 185(7), 1371-1380.
52. Martinovic, I.; Abegunewardene, N.; Seul, M.; Vosseler, M.; Horstick, G.; Buerke, M.; Darius, H.; Lindemann, S. Elevated monocyte chemoattractant protein-1 serum levels in patients at risk for coronary artery disease. Circ. J., 2005, 69(12), 1484-1489.
53. Gu, L.; Okada, Y.; Clinton, S. K.; Gerard, C.; Sukhova, G. K.; Libby, P.; Rollins, B. J. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptordeficient mice. Mol. Cell, 1998, 2(2), 275-281.
54. Boring, L.; Gosling, J.; Cleary, M.; Charo, I. F. Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis. Nature, 1998, 394(6696), 894-897.
55. Veillard, N. R.; Steffens, S.; Pelli, G.; Lu, B.; Kwak, B. R.; Gerard, C.; Charo, I. F.; Mach, F. Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation, 2005, 112(6), 870-878.
56. Zhang, Y. J.; Rutledge, B. J.; Rollins, B. J. Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis. Identification of a mutated protein that inhibits MCP-1-mediated monocyte chemotaxis. J. Biol. Chem., 1994, 269(22), 15918-15924.
57. Inoue, S.; Egashira, K.; Ni, W.; Kitamoto, S.; Usui, M.; Otani, K.; Ishibashi, M.; Hiasa, K.; Nishida, K.; Takeshita, A. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein Eknockout mice. Circulation, 2002, 106(21), 2700-2706.
58. Tarzami, S. T.; Cheng, R.; Miao, W.; Kitsis, R. N.; Berman, J. W. Chemokine expression in myocardial ischemia: MIP-2 dependent MCP-1 expression protects cardiomyocytes from cell death. J. Mol. Cell. Cardiol., 2002, 34(2), 209-221.
59. Dewald, O.; Zymek, P.; Winkelmann, K.; Koerting, A.; Ren, G.; Abou-Khamis, T.; Michael, L. H.; Rollins, B. J.; Entman, M. L.; Frangogiannis, N. G. CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ. Res., 2005, 96(8), 881-889.
60. Piccinini, A. M.; Knebl, K.; Rek, A.; Wildner, G.; Diedrichs-Mohring, M.; Kungl, A. J. Rationally evolving MCP-1/CCL2 into a decoy protein with potent anti-inflammatory activity in vivo. J. Biol. Chem., 2010, 285(12), 8782-8792.
61. Liehn, E. A.; Piccinini, A. M.; Koenen, R. R.; Soehnlein, O.; Adage, T.; Fatu, R.; Curaj, A.; Popescu, A.; Zernecke, A.; Kungl, A. J.; Weber, C. A new MCP-1/CCL2 competitor limiting neointima formation and myocardial ischemia-reperfusion injury in mice. J. Am. Coll. Cardiol., 2010, 56(22), 1847-1857.
62. Bizzarri, C.; Beccari, A. R.; Bertini, R.; Cavicchia, M. R.; Giorgini, S.; Allegretti, M. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacol. Ther., 2006, 112(1), 139-149.
63. Belperio, J. A.; Keane, M. P.; Arenberg, D. A.; Addison, C. L.; Ehlert, J. E.; Burdick, M. D.; Strieter, R. M. CXC chemokines in angiogenesis. J. Leukoc. Biol., 2000, 68(1), 1-8.
64. Strieter, R. M.; Polverini, P. J.; Kunkel, S. L.; Arenberg, D. A.; Burdick, M. D.; Kasper, J.; Dzuiba, J.; Van Damme, J.; Walz, A.; Marriott, D.; et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem., 1995, 270(45), 27348-27357.
65. Jin, D. K.; Shido, K.; Kopp, H. G.; Petit, I.; Shmelkov, S. V.; Young, L. M.; Hooper, A. T.; Amano, H.; Avecilla, S. T.; Heissig, B.; Hattori, K.; Zhang, F.; Hicklin, D. J.; Wu, Y.; Zhu, Z.; Dunn, A.; Salari, H.; Werb, Z.; Hackett, N. R.; Crystal, R. G.; Lyden, D.; Rafii, S. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat. Med., 2006, 12(5), 557-567.
66. Liehn, E. A.; Schober, A.; Weber, C. Blockade of keratinocytederived chemokine inhibits endothelial recovery and enhances plaque formation after arterial injury in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol., 2004, 24(10), 1891-1896.
67. Bless, N. M.; Warner, R. L.; Padgaonkar, V. A.; Lentsch, A. B.; Czermak, B. J.; Schmal, H.; Friedl, H. P.; Ward, P. A. Roles for CX-C chemokines and C5a in lung injury after hindlimb ischemiareperfusion. Am. J. Physiol., 1999, 276(1 Pt 1), L57-63.
68. Boyle, E. M., Jr.; Kovacich, J. C.; Hebert, C. A.; Canty, T. G., Jr.; Chi, E.; Morgan, E. N.; Pohlman, T. H.; Verrier, E. D. Inhibition of interleukin-8 blocks myocardial ischemia-reperfusion injury. J. Thorac. Cardiovasc. Surg., 1998, 116(1), 114-121.
69. Cerqueira, N. F.; Hussni, C. A.; Yoshida, W. B. Pathophysiology of mesenteric ischemia/reperfusion: a review. Acta Cir Bras, 2005, 20(4), 336-343.
70. Kaneko, H.; Tamura, A.; Ishii, T.; Maeda, T.; Katagiri, T.; Ishii, J.; Kubota, Y.; Suzuki, T.; Tsuchiya, M.; Otsuka, Y.; Yamazaki, K.; Watanabe, M.; Tatsuo, T. Bacterial translocation in small intestinal ischemia-reperfusion injury and efficacy of Anti-CINC antibody treatment. Eur. Surg. Res., 2007, 39(3), 153-159.
71. Miura, M.; Fu, X.; Zhang, Q. W.; Remick, D. G.; Fairchild, R. L. Neutralization of Gro alpha and macrophage inflammatory protein-2 attenuates renal ischemia/reperfusion injury. Am. J. Pathol., 2001, 159(6), 2137-2145.
72. Campbell, J. J.; Hedrick, J.; Zlotnik, A.; Siani, M. A.; Thompson, D. A.; Butcher, E. C. Chemokines and the arrest of lymphocytes rolling under flow conditions. Science, 1998, 279(5349), 381-384.
73. Martin, C.; Burdon, P. C.; Bridger, G.; Gutierrez-Ramos, J. C.; Williams, T. J.; Rankin, S. M. Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. Immunity, 2003, 19(4), 583-593.
74. Broxmeyer, H. E.; Orschell, C. M.; Clapp, D. W.; Hangoc, G.; Cooper, S.; Plett, P. A.; Liles, W. C.; Li, X.; Graham-Evans, B.; Campbell, T. B.; Calandra, G.; Bridger, G.; Dale, D. C.; Srour, E. F. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp. Med., 2005, 201(8), 1307-1318.
75. Mieno, S.; Ramlawi, B.; Boodhwani, M.; Clements, R. T.; Minamimura, K.; Maki, T.; Xu, S. H.; Bianchi, C.; Li, J.; Sellke, F. W. Role of stromal-derived factor-1alpha in the induction of circulating CD34+CXCR4+ progenitor cells after cardiac surgery. Circulation, 2006, 114(1 Suppl), I186-192.
76. Stellos, K.; Bigalke, B.; Langer, H.; Geisler, T.; Schad, A.; Kogel, A.; Pfaff, F.; Stakos, D.; Seizer, P.; Muller, I.; Htun, P.; Lindemann, S.; Gawaz, M. Expression of stromal-cell-derived factor-1 on circulating platelets is increased in patients with acute coronary syndrome and correlates with the number of CD34+ progenitor cells. Eur. Heart J., 2009, 30(5), 584-593.
77. Damas, J. K.; Waehre, T.; Yndestad, A.; Ueland, T.; Muller, F.; Eiken, H. G.; Holm, A. M.; Halvorsen, B.; Froland, S. S.; Gullestad, L.; Aukrust, P. Stromal cell-derived factor-1alpha in unstable angina: potential antiinflammatory and matrix-stabilizing effects. Circulation, 2002, 106(1), 36-42.
78. Kowalska, M. A.; Ratajczak, M. Z.; Majka, M.; Jin, J.; Kunapuli, S.; Brass, L.; Poncz, M. Stromal cell-derived factor-1 and macrophage-derived chemokine: 2 chemokines that activate platelets. Blood, 2000, 96(1), 50-57.
79. Abi-Younes, S.; Sauty, A.; Mach, F.; Sukhova, G. K.; Libby, P.; Luster, A. D. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ. Res., 2000, 86(2), 131-138.
80. Karshovska, E.; Zagorac, D.; Zernecke, A.; Weber, C.; Schober, A. A small molecule CXCR4 antagonist inhibits neointima formation and smooth muscle progenitor cell mobilization after arterial injury. J. Thromb. Haemost., 2008, 6(10), 1812-1815.
81. van Wanrooij, E. J.; Happe, H.; Hauer, A. D.; de Vos, P.; Imanishi, T.; Fujiwara, H.; van Berkel, T. J.; Kuiper, J. HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol., 2005, 25(12), 2642-2647.
82. Abu Nabah, Y. N.; Losada, M.; Estelles, R.; Mateo, T.; Company, C.; Piqueras, L.; Lopez-Gines, C.; Sarau, H.; Cortijo, J.; Morcillo, E. J.; Jose, P. J.; Sanz, M. J. CXCR2 blockade impairs angiotensin II-induced CC chemokine synthesis and mononuclear leukocyte infiltration. Arterioscler. Thromb. Vasc. Biol., 2007, 27(11), 2370-2376.
83. Zernecke, A.; Bot, I.; Djalali-Talab, Y.; Shagdarsuren, E.; Bidzhekov, K.; Meiler, S.; Krohn, R.; Schober, A.; Sperandio, M.; Soehnlein, O.; Bornemann, J.; Tacke, F.; Biessen, E. A.; Weber, C. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ. Res., 2008, 102(2), 209-217.
84. Proulx, C.; El-Helou, V.; Gosselin, H.; Clement, R.; Gillis, M. A.; Villeneuve, L.; Calderone, A. Antagonism of stromal cell-derived factor-1alpha reduces infarct size and improves ventricular function after myocardial infarction. Pflugers Arch., 2007, 455(2), 241-250.
85. Saxena, A.; Fish, J. E.; White, M. D.; Yu, S.; Smyth, J. W.; Shaw, R. M.; DiMaio, J. M.; Srivastava, D. Stromal cell-derived factor-1alpha is cardioprotective after myocardial infarction. Circulation, 2008, 117(17), 2224-2231.
86. Zhang, M.; Mal, N.; Kiedrowski, M.; Chacko, M.; Askari, A. T.; Popovic, Z. B.; Koc, O. N.; Penn, M. S. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J., 2007, 21(12), 3197-3207.
87. Zhang, K.; McQuibban, G. A.; Silva, C.; Butler, G. S.; Johnston, J. B.; Holden, J.; Clark-Lewis, I.; Overall, C. M.; Power, C. HIVinduced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nat. Neurosci., 2003, 6(10), 1064-1071.
88. Segers, V. F.; Tokunou, T.; Higgins, L. J.; MacGillivray, C.; Gannon, J.; Lee, R. T. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation, 2007, 116(15), 1683-1692.
89. Zernecke, A.; Bernhagen, J.; Weber, C. Macrophage migration inhibitory factor in cardiovascular disease. Circulation, 2008, 117(12), 1594-1602.
90. Herder, C.; Illig, T.; Baumert, J.; Muller, M.; Klopp, N.; Khuseyinova, N.; Meisinger, C.; Martin, S.; Thorand, B.; Koenig, W. Macrophage migration inhibitory factor (MIF) and risk for coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Atherosclerosis, 2008, 200(2), 380-388.
91. Sun, H. W.; Bernhagen, J.; Bucala, R.; Lolis, E. Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc. Natl. Acad. Sci. U. S. A., 1996, 93(11), 5191-5196.
92. Bernhagen, J.; Krohn, R.; Lue, H.; Gregory, J. L.; Zernecke, A.; Koenen, R. R.; Dewor, M.; Georgiev, I.; Schober, A.; Leng, L.; Kooistra, T.; Fingerle-Rowson, G.; Ghezzi, P.; Kleemann, R.; McColl, S. R.; Bucala, R.; Hickey, M. J.; Weber, C. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med., 2007, 13(5), 587-596.
93. Burger-Kentischer, A.; Gobel, H.; Kleemann, R.; Zernecke, A.; Bucala, R.; Leng, L.; Finkelmeier, D.; Geiger, G.; Schaefer, H. E.; Schober, A.; Weber, C.; Brunner, H.; Rutten, H.; Ihling, C.; Bernhagen, J. Reduction of the aortic inflammatory response in spontaneous atherosclerosis by blockade of macrophage migration inhibitory factor (MIF). Atherosclerosis, 2006, 184(1), 28-38.
94. Miller, E. J.; Li, J.; Leng, L.; McDonald, C.; Atsumi, T.; Bucala, R.; Young, L. H. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature, 2008, 451(7178), 578-582.
95. Shiraha, H.; Glading, A.; Gupta, K.; Wells, A. IP-10 inhibits epidermal growth factor-induced motility by decreasing epidermal growth factor receptor-mediated calpain activity. J. Cell Biol., 1999, 146(1), 243-254.
96. Koten, K.; Hirohata, S.; Miyoshi, T.; Ogawa, H.; Usui, S.; Shinohata, R.; Iwamoto, M.; Kitawaki, T.; Kusachi, S.; Sakaguchi, K.; Ohe, T. Serum interferon-gamma-inducible protein 10 level was increased in myocardial infarction patients, and negatively correlated with infarct size. Clin. Biochem., 2008, 41(1-2), 30-37.
97. Crescioli, C.; Buonamano, A.; Scolletta, S.; Sottili, M.; Francalanci, M.; Giomarelli, P.; Biagioli, B.; Lisi, G.; Pradella, F.; Serio, M.; Romagnani, P.; Maccherini, M. Predictive role of pretransplant serum CXCL10 for cardiac acute rejection. Transplantation, 2009, 87(2), 249-255.
98. King, V. L.; Lin, A. Y.; Kristo, F.; Anderson, T. J.; Ahluwalia, N.; Hardy, G. J.; Owens, A. P., 3rd; Howatt, D. A.; Shen, D.; Tager, A. M.; Luster, A. D.; Daugherty, A.; Gerszten, R. E. Interferongamma and the interferon-inducible chemokine CXCL10 protect against aneurysm formation and rupture. Circulation, 2009, 119(3), 426-435.
99. Frangogiannis, N. G. Chemokines in the ischemic myocardium: from inflammation to fibrosis. Inflamm. Res., 2004, 53(11), 585-595.
100. Frangogiannis, N. G. The role of the chemokines in myocardial ischemia and reperfusion. Curr. Vasc. Pharmacol., 2004, 2(2), 163-174.
101. Byrne, F. R.; Winters, A.; Brankow, D.; Hu, S.; Juan, T.; Steavenson, S.; Doellgast, G.; Kuchimanchi, K.; Brown, H.; Anderson, S.; Smelt, S.; Sullivan, T.; Alcorn, D.; Tocker, J.; Dean, C., Jr.; Macmaster, J.; Kirchner, J.; Buys, J.; Manoukian, R.; Jiao, E.; Zou, X.; Campanella, G. S.; Siu, G. An antibody to IP-10 is a potent antagonist of cell migration in vitro and in vivo and does not affect disease in several animal models of inflammation. Autoimmunity, 2009, 42(3), 171-182.
102. Garton, K. J.; Gough, P. J.; Blobel, C. P.; Murphy, G.; Greaves, D. R.; Dempsey, P. J.; Raines, E. W. Tumor necrosis factor-alphaconverting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J. Biol. Chem., 2001, 276(41), 37993-38001.
103. Bazan, J. F.; Bacon, K. B.; Hardiman, G.; Wang, W.; Soo, K.; Rossi, D.; Greaves, D. R.; Zlotnik, A.; Schall, T. J. A new class of membrane-bound chemokine with a CX3C motif. Nature, 1997, 385(6617), 640-644.
104. D'Haese, J. G.; Demir, I. E.; Friess, H.; Ceyhan, G. O. Fractalkine/ CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential. Expert Opin. Ther. Targets, 2010, 14(2), 207-219.
105. Sicinska, J.; Gorska, E.; Cicha, M.; Kuklo-Kowalska, A.; Hamze, V.; Stepien, K.; Wasik, M.; Rudnicka, L. Increased serum fractalkine in systemic sclerosis. Down-regulation by prostaglandin E1. Clin. Exp. Rheumatol., 2008, 26(4), 527-533.
106. Matsunawa, M.; Isozaki, T.; Odai, T.; Yajima, N.; Takeuchi, H. T.; Negishi, M.; Ide, H.; Adachi, M.; Kasama, T. Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis. Arthritis Rheum., 2006, 54(11), 3408-3416.
107. Kastenbauer, S.; Koedel, U.; Wick, M.; Kieseier, B. C.; Hartung, H. P.; Pfister, H. W. CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system. J. Neuroimmunol., 2003, 137(1-2), 210-217.
108. Maegdefessel, L.; Schlitt, A.; Pippig, S.; Schwaab, B.; Fingscheidt, K.; Raaz, U.; Buerke, M.; Loppnow, H. Patients with insulindependent diabetes or coronary heart disease following rehabilitation express serum fractalkine levels similar to those in healthy control subjects. Vasc Health Risk Manag, 2009, 5, 849-857.
109. Teupser, D.; Pavlides, S.; Tan, M.; Gutierrez-Ramos, J. C.; Kolbeck, R.; Breslow, J. L. Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. Proc. Natl. Acad. Sci. U. S. A., 2004, 101(51), 17795-17800.
110. Husberg, C.; Nygard, S.; Finsen, A. V.; Damas, J. K.; Frigessi, A.; Oie, E.; Waehre, A.; Gullestad, L.; Aukrust, P.; Yndestad, A.; Christensen, G. Cytokine expression profiling of the myocardium reveals a role for CX3CL1 (fractalkine) in heart failure. J. Mol. Cell. Cardiol., 2008, 45(2), 261-269.
111. Dorgham, K.; Ghadiri, A.; Hermand, P.; Rodero, M.; Poupel, L.; Iga, M.; Hartley, O.; Gorochov, G.; Combadiere, C.; Deterre, P. An engineered CX3CR1 antagonist endowed with anti-inflammatory activity. J. Leukoc. Biol., 2009, 86(4), 903-911.
112. Haringman, J. J.; Kraan, M. C.; Smeets, T. J.; Zwinderman, K. H.; Tak, P. P. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann. Rheum. Dis., 2003, 62(8), 715-721.
113. Zymek, P.; Nah, D. Y.; Bujak, M.; Ren, G.; Koerting, A.; Leucker, T.; Huebener, P.; Taffet, G.; Entman, M.; Frangogiannis, N. G. Interleukin-10 is not a critical regulator of infarct healing and left ventricular remodeling. Cardiovasc. Res., 2007, 74(2), 313-322.